Molecular Recognition of Protein Kinase Binding Pockets for Design of Potent and Selective Kinase Inhibitors

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1

Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

The protein kinase complement of the human genome

Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145

Docking and scoring in virtual screening for drug discovery: methods and applications

Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1549 · Cited by 4,150

Oncogenic kinase signalling.

Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738

Drug-like properties and the causes of poor solubility and poor permeability

Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734

Specificity and mechanism of action of some commonly used protein kinase inhibitors

DAVIES, S. P., REDDY, H., CAIVANO, M., & COHEN, P. (2000) · Biochemical Journal · doi:10.1042/bj3510095 · Cited by 3,132

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967

Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension

Uehata, M., Ishizaki, T., Satoh, H., Ono, T., Kawahara, T., Morishita, T., Tamakawa, H., Yamagami, K., Inui, J., Maekawa, M., et al. (1997) · Nature · doi:10.1038/40187 · Cited by 2,859

Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification.

Hanks, S. K., & Hunter, T. R. (1995) · PubMed · Cited by 2,518

The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification 1

Hanks, S. K., & Hunter, T. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.8.7768349 · Cited by 2,318

A geometric approach to macromolecule-ligand interactions

Kuntz, I. D., Blaney, J. M., Oatley, S. J., Langridge, R., & Ferrin, T. E. (1982) · Journal of Molecular Biology · doi:10.1016/0022-2836(82)90153-x · Cited by 2,278

Protein kinases — the major drug targets of the twenty-first century?

Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,186

GSK-3: tricks of the trade for a multi-tasking kinase

Doble, B. W., & Woodgett, J. R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00384 · Cited by 2,084

The Fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in C. elegans

Ogg, S., Paradis, S., Gottlieb, S., Patterson, G. I., Lee, L., Tissenbaum, H. A., & Ruvkun, G. (1997) · Nature · doi:10.1038/40194 · Cited by 1,932

A Critical Assessment of Docking Programs and Scoring Functions

Warren, G. L., Andrews, C. W., Capelli, A.-M., Clarke, B., LaLonde, J., Lambert, M. H., Lindvall, M., Nevins, N., Semus, S. F., Senger, S., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050362n · Cited by 1,814

Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase

Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780

The Conformational Plasticity of Protein Kinases

Huse, M., & Kuriyan, J. (2002) · Cell · doi:10.1016/s0092-8674(02)00741-9 · Cited by 1,752

Halogen bonds in biological molecules

Auffinger, P., Hays, F. A., Westhof, E., & Ho, P. S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407607101 · Cited by 1,634

Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor

Stamos, J., Sliwkowski, M. X., & Eigenbrot, C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207135200 · Cited by 1,574

Synthesis of Macroporous Minerals with Highly Ordered Three-Dimensional Arrays of Spheroidal Voids

Holland, B. T., Blanford, C. F., & Stein, A. (1998) · Science · doi:10.1126/science.281.5376.538 · Cited by 1,484

The specificities of protein kinase inhibitors: an update

BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369

A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers

Bischoff, J. R. (1998) · The EMBO Journal · doi:10.1093/emboj/17.11.3052 · Cited by 1,216

Crystal structure of the Src family tyrosine kinase Hck

Sicheri, F., Moarefi, I., & Kuriyan, J. (1997) · Nature · doi:10.1038/385602a0 · Cited by 1,172

Regulation of Protein Kinases

Nolen, B., Taylor, S., & Ghosh, G. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.08.024 · Cited by 1,167

Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

Faivre, S., Delbaldo, C., Vera, K., Robert, C., Lozahic, S., Lassau, N., Bello, C., Deprimo, S., Brega, N., Massimini, G., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2194 · Cited by 1,164

Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors

Mohammadi, M., McMahon, G., Sun, L., Tang, C., Hirth, P., Yeh, B. K., Hubbard, S. R., & Schlessinger, J. (1997) · Science · doi:10.1126/science.276.5314.955 · Cited by 1,097

Crystal structure of the tyrosine kinase domain of the human insulin receptor

Hubbard, S. R., Wei, L., & Hendrickson, W. A. (1994) · Nature · doi:10.1038/372746a0 · Cited by 1,080

A Bioavailability Score

Martin, Y. C. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0492002 · Cited by 1,020

Crystal structure of cyclin-dependent kinase 2

De Bondt, H. L., Rosenblatt, J., Jancarik, J., Jones, H. D., Morgan, D. O., & Kim, S.-H. (1993) · Nature · doi:10.1038/363595a0 · Cited by 976

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

Harrington, E. A., Bebbington, D., Moore, J., Rasmussen, R. K., Ajose-Adeogun, A. O., Nakayama, T., Graham, J. A., Demur, C., Hercend, T., Diu-Hercend, A., et al. (2004) · Nature Medicine · doi:10.1038/nm1003 · Cited by 965

Structure of a Peptide Inhibitor Bound to the Catalytic Subunit of Cyclic Adenosine Monophosphate-Dependent Protein Kinase

Knighton, D. R., Zheng, J., Ten Eyck, L. F., Xuong, N.-H., Taylor, S. S., & Sowadski, J. M. (1991) · Science · doi:10.1126/science.1862343 · Cited by 960

Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase

Nagar, B., Hantschel, O., Young, M. A., Scheffzek, K., Veach, D., Bornmann, W., Clarkson, B., Superti-Furga, G., & Kuriyan, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00194-6 · Cited by 879

Approaches to the Description and Prediction of the Binding Affinity of Small-Molecule Ligands to Macromolecular Receptors

Gohlke, H., & Klebe, G. (2002) · Angewandte Chemie International Edition · doi:10.1002/1521-3773(20020802)41:15<2644::aid-anie2644>3.0.co;2-o · Cited by 843

Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site

Pargellis, C., Tong, L., Churchill, L., Cirillo, P. F., Gilmore, T., Graham, A. G., Grob, P. M., Hickey, E. R., Moss, N., Pav, S., et al. (2002) · Nature Structural Biology · doi:10.1038/nsb770 · Cited by 833

Inhibition of Cyclin‐Dependent Kinases by Purine Analogues: Crystal Structure of Human cdk2 Complexed with Roscovitine

De Azevedo, W. F., Leclerc, S., Meijer, L., Havlicek, L., Strnad, M., & Kim, S. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.0518a.x · Cited by 729

Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia

Druker, B. J., & Lydon, N. B. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9083 · Cited by 707

Features of Selective Kinase Inhibitors

Knight, Z. A., & Shokat, K. M. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.04.011 · Cited by 657

Structural Basis of Aurora-A Activation by TPX2 at the Mitotic Spindle

Bayliss, R., Sardon, T., Vernos, I., & Conti, E. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00392-7 · Cited by 636

Inhibition of Cyclin‐Dependent Kinases by Purine Analogues

Veselý, J., Havliček, L., Strnad, M., Blow, J. J., Donella‐Deana, A., Pinna, L., Letham, D. S., Kato, J., Detivaud, L., Leclerc, S., et al. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.00771.x · Cited by 632

Polyketide and Nonribosomal Peptide Antibiotics: Modularity and Versatility

Walsh, C. T. (2004) · Science · doi:10.1126/science.1094318 · Cited by 628

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

Ohren, J. F., Chen, H., Pavlovsky, A., Whitehead, C., Zhang, E., Kuffa, P., Yan, C., McConnell, P., Spessard, C., Banotai, C., et al. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb859 · Cited by 626

Kinetics of Response in Lymphoid Tissues to Antiretroviral Therapy of HIV-1 Infection

Cavert, W., Notermans, D. W., Staskus, K., Wietgrefe, S. W., Zupancic, M., Gebhard, K., Henry, K., Zhang, Z.-Q., Mills, R., McDade, H., et al. (1997) · Science · doi:10.1126/science.276.5314.960 · Cited by 622

Rho kinase, a promising drug target for neurological disorders

Mueller, B. K., Mack, H., & Teusch, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1719 · Cited by 608

Property-Based Design: Optimization of Drug Absorption and Pharmacokinetics

van de Waterbeemd, H., Smith, D. A., Beaumont, K., & Walker, D. K. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm000407e · Cited by 599

Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

Barker, A. J., Gibson, K. H., Grundy, W., Godfrey, A. A., Barlow, J. J., Healy, M. P., Woodburn, J. R., Ashton, S. E., Curry, B. J., Scarlett, L., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00344-4 · Cited by 569

The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases

Brown, N. R., Noble, M. E. M., Endicott, J. A., & Johnson, L. N. (1999) · Nature Cell Biology · doi:10.1038/15674 · Cited by 546

A general pattern for substrate recognition by P‐glycoprotein

Seelig, A. (1998) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1998.2510252.x · Cited by 527

Issues and progress with protein kinase inhibitors for cancer treatment

Dancey, J., & Sausville, E. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1066 · Cited by 526

Crystal structure of an activated Akt/Protein Kinase B ternary complex with GSK3-peptide and AMP-PNP

Yang, J., Cron, P., Good, V. M., Thompson, V., Hemmings, B. A., & Barford, D. (2002) · Nature Structural Biology · doi:10.1038/nsb870 · Cited by 503

The Structural Basis for Autoinhibition of FLT3 by the Juxtamembrane Domain

Griffith, J., Black, J., Faerman, C., Swenson, L., Wynn, M., Lu, F., Lippke, J., & Saxena, K. (2004) · Molecular Cell · doi:10.1016/s1097-2765(03)00505-7 · Cited by 499

Global Topology Analysis of the Escherichia coli Inner Membrane Proteome

Daley, D. O., Rapp, M., Granseth, E., Melén, K., Drew, D., & von Heijne, G. (2005) · Science · doi:10.1126/science.1109730 · Cited by 490

Crystal Structure of Hck in Complex with a Src Family–Selective Tyrosine Kinase Inhibitor

Schindler, T., Sicheri, F., Pico, A., Gazit, A., Levitzki, A., & Kuriyan, J. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80357-3 · Cited by 430

Roscovitine and Other Purines as Kinase Inhibitors. From Starfish Oocytes to Clinical Trials

Meijer, L., & Raymond, E. (2003) · ChemInform · doi:10.1002/chin.200336265 · Cited by 362

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs

Fabbro, D., Ruetz, S., Buchdunger, E., Cowan-Jacob, S. W., Fendrich, G., Liebetanz, J., Mestan, J., O'Reilly, T., Traxler, P., Chaudhuri, B., et al. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00179-1 · Cited by 335

Cyclin-Dependent Kinase Inhibitors: Useful Targets in Cell Cycle Regulation

Sielecki, T. M., Boylan, J. F., Benfield, P. A., & Trainor, G. L. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990256j · Cited by 323

Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm

Shimokawa, H. (1999) · Cardiovascular Research · doi:10.1016/s0008-6363(99)00144-3 · Cited by 317

Multiple modes of ligand recognition: Crystal structures of cyclin‐dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine

Schulze‐Gahmen, U., Brandsen, J., Jones, H. D., Morgan, D. O., Meijer, L., Vesely, J., & Kim, S. (1995) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.340220408 · Cited by 279

Structure of the Kinase Domain of an Imatinib-Resistant Abl Mutant in Complex with the Aurora Kinase Inhibitor VX-680

Young, M. A., Shah, N. P., Chao, L. H., Seeliger, M., Milanov, Z. V., Biggs, W. H., Treiber, D. K., Patel, H. K., Zarrinkar, P. P., Lockhart, D. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2788 · Cited by 276

Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors

Chang, Y.-T., Gray, N. S., Rosania, G. R., Sutherlin, D. P., Kwon, S., Norman, T. C., Sarohia, R., Leost, M., Meijer, L., & Schultz, P. G. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)80048-9 · Cited by 268

The Structure of Dimeric ROCK I Reveals the Mechanism for Ligand Selectivity

Jacobs, M., Hayakawa, K., Swenson, L., Bellon, S., Fleming, M., Taslimi, P., & Doran, J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508847200 · Cited by 261

N-(Cycloalkylamino)acyl-2-aminothiazole Inhibitors of Cyclin-Dependent Kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective Antitumor Agent

Misra, R. N., Xiao, H.-Y., Kim, K. S., Lu, S., Han, W.-C., Barbosa, S. A., Hunt, J. T., Rawlins, D. B., Shan, W., Ahmed, S. Z., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0305568 · Cited by 252

Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives

Zimmermann, J., Buchdunger, E., Mett, H., Meyer, T., & Lydon, N. B. (1997) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(96)00601-4 · Cited by 247

Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma

Ahmad, T., & Eisen, T. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-040028 · Cited by 244

Small-molecule cyclin-dependent kinase modulators

Senderowicz, A. M. (2003) · Oncogene · doi:10.1038/sj.onc.1206954 · Cited by 236

Binding Mode of the 4-Anilinoquinazoline Class of Protein Kinase Inhibitor: X-ray Crystallographic Studies of 4-Anilinoquinazolines Bound to Cyclin-Dependent Kinase 2 and p38 Kinase

Shewchuk, L., Hassell, A., Wisely, B., Rocque, W., Holmes, W., Veal, J., & Kuyper, L. F. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990401t · Cited by 233

Structures of the Cancer-Related Aurora-A, FAK, and EphA2 Protein Kinases from Nanovolume Crystallography

Nowakowski, J., Cronin, C. N., McRee, D. E., Knuth, M. W., Nelson, C. G., Pavletich, N. P., Rogers, J., Sang, B.-C., Scheibe, D. N., Swanson, R. V., et al. (2002) · Structure · doi:10.1016/s0969-2126(02)00907-3 · Cited by 222

High-Resolution Crystal Structures of Human Cyclin-Dependent Kinase 2 with and without ATP: Bound Waters and Natural Ligand as Guides for Inhibitor Design

Schulze-Gahmen, U., De Bondt, H. L., & Kim, S.-H. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm960402a · Cited by 211

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML

O'Hare, T., Pollock, R., Stoffregen, E. P., Keats, J. A., Abdullah, O. M., Moseson, E. M., Rivera, V. M., Tang, H., Metcalf, C. A., Bohacek, R. S., et al. (2004) · Blood · doi:10.1182/blood-2004-05-1851 · Cited by 200

Angiogenesis inhibitors in clinical development; where are we now and where are we going?

Eskens, F. A. L. M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601401 · Cited by 197

Respiration and Parturition Affected by Conditional Overexpression of the Ca 2+ -Activated K + Channel Subunit, SK3

Bond, C. T., Sprengel, R., Bissonnette, J. M., Kaufmann, W. A., Pribnow, D., Neelands, T., Storck, T., Baetscher, M., Jerecic, J., Maylie, J., et al. (2000) · Science · doi:10.1126/science.289.5486.1942 · Cited by 184

A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo

Missbach, M., Jeschke, M., Feyen, J., Müller, K., Glatt, M., Green, J., & Šuša, M. (1999) · Bone · doi:10.1016/s8756-3282(99)00020-4 · Cited by 168

Protein Kinase A in Complex with Rho-Kinase Inhibitors Y-27632, Fasudil, and H-1152P

Breitenlechner, C. B., Gaßel, M., Hidaka, H., Kinzel, V., Huber, R., Engh, R. A., & Bossemeyer, D. (2003) · Structure · doi:10.1016/j.str.2003.11.002 · Cited by 162

Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors

Miyazaki, Y., Matsunaga, S., Tang, J., Maeda, Y., Nakano, M., Philippe, R. J., Shibahara, M., Liu, W., Sato, H., Wang, L., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.03.034 · Cited by 158

Kinomics: characterizing the therapeutically validated kinase space

Vieth, M., Sutherland, J. J., Robertson, D. H., & Campbell, R. M. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03477-x · Cited by 157

Design and Discovery of Small Molecules Targeting Raf-1 Kinase

Lowinger, T. B., Riedl, B., Dumas, J., & Smith, R. A. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023393125 · Cited by 150

The Replacement of ATP by the Competitive Inhibitor Emodin Induces Conformational Modifications in the Catalytic Site of Protein Kinase CK2

Battistutta, R., Sarno, S., Moliner, E. D., Papinutto, E., Zanotti, G., & Pinna, L. A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004257200 · Cited by 148

Potent and Selective Aurora Inhibitors Identified by the Expansion of a Novel Scaffold for Protein Kinase Inhibition

Fancelli, D., Berta, D. G., Bindi, S., Cameron, A. D., Cappella, P., Carpinelli, P., Catana, C., Forte, B., Giordano, P., Giorgini, M. L., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049076m · Cited by 146

The Akt/PKB Family of Protein Kinases: A Review of Small Molecule Inhibitors and Progress Towards Target Validation

Barnett, S., Bilodeau, M. T., & Lindsley, C. W. (2005) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026053507714 · Cited by 146

Structure−Activity Relationships for a Novel Series of Pyrido[2,3-d]pyrimidine Tyrosine Kinase Inhibitors

Hamby, J. M., Connolly, C. J. C., Schroeder, M. C., Winters, R. T., Showalter, H. D. H., Panek, R. L., Major, T. C., Olsewski, B., Ryan, M. J., Dahring, T. K., et al. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm970367n · Cited by 142

Discovery and Evaluation of 2-Anilino-5-aryloxazoles as a Novel Class of VEGFR2 Kinase Inhibitors

Harris, P. A., Cheung, M., Hunter, R., Brown, M. L., Veal, J. M., Nolte, R. T., Wang, L., Liu, W. J., Crosby, R. M., Johnson, J. H., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049538w · Cited by 137

SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors

Heron, N. M., Anderson, M., Blowers, D. P., Breed, J., Eden, J. M., Green, S., Hill, G. B., Johnson, T., Jung, F. H., McMiken, H. H. J., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.11.053 · Cited by 128

Sunitinib malate for the treatment of solid tumours: a review of current clinical data

Motzer, R. J., Hoosen, S., Bello, C. L., & Christensen, J. G. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.5.553 · Cited by 119

Inspecting the Structure-Activity Relationship of Protein Kinase CK2 Inhibitors Derived from Tetrabromo-Benzimidazole

Battistutta, R., Mazzorana, M., Sarno, S., Kazimierczuk, Z., Zanotti, G., & Pinna, L. A. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.08.015 · Cited by 118

Novel 4‐Amino‐furo[2,3‐d]pyrimidines as Tie‐2 and VEGFR2 Dual Inhibitors.

Miyazaki, Y., & al., E. A. E. (2005) · ChemInform · doi:10.1002/chin.200536152 · Cited by 115

H-Series Protein Kinase Inhibitors and Potential Clinical Applications

Ono-Saito, N., Niki, I., & Hidaka, H. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00070-9 · Cited by 108

Clinical anticancer drug development: targeting the cyclin-dependent kinases

Benson, C., Kaye, S. B., Workman, P., Garrett, M. D., Walton, M., & Bono, J. S. D. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602229 · Cited by 103

The Raison D'Être of Constitutively Active Protein Kinases: The Lesson of CK2

Pinna, L. A. (2003) · Accounts of Chemical Research · doi:10.1021/ar020164f · Cited by 100

Structural Basis of Src Tyrosine Kinase Inhibition with a New Class of Potent and Selective Trisubstituted Purine‐based Compounds

Dalgarno, D. C., Stehle, T., Narula, S. S., Schelling, P., van Schravendijk, M. R., Adams, S. E., Andrade, L. J., Keats, J. A., Ram, M. K., Jin, L., et al. (2005) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2005.00316.x · Cited by 87

Drugging Cell Cycle Kinases in Cancer Therapy

Blagden, S. P., & Bono, J. S. D. (2005) · Current Drug Targets · doi:10.2174/1389450053765824 · Cited by 86

From the Insoluble Dye Indirubin towards Highly Active, Soluble CDK2‐Inhibitors

Jautelat, R., Brumby, T., Schäfer, M., Briem, H., Eisenbrand, G., Schwahn, S., Krüger, M., Lücking, U., Prien, O., & Siemeister, G. (2005) · ChemBioChem · doi:10.1002/cbic.200400108 · Cited by 80

Crystal Structures of Active Src Kinase Domain Complexes

Breitenlechner, C. B., Kairies, N., Honold, K., Scheiblich, S., Koll, H., Greiter, E., Koch, S., Schäfer, W., Huber, R., & Engh, R. A. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.08.023 · Cited by 76

Progress in the Development of Selective Inhibitors of Aurora Kinases

Mortlock, A. A., Keen, N., Jung, F. H., et al. (2005) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026054637719 · Cited by 75

Progress Towards Therapeutic Small Molecule MEK Inhibitors for Use in Cancer Therapy

Wallace, E. M., Lyssikatos, J. P., Yeh, T. C., Winkler, J. D., & Koch, K. M. (2005) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026053507723 · Cited by 70

Dual tyrosine kinase inhibitors in chronic myeloid leukemia

Martinelli, G., Soverini, S., Rosti, G., & Baccarani, M. (2005) · Leukemia · doi:10.1038/sj.leu.2403950 · Cited by 67

Editorial: Drug Discovery Process for Kinease Inhibitors

Weinmann, H., & Metternich, R. E. (2005) · ChemBioChem · doi:10.1002/cbic.200500034 · Cited by 65

Crystal Structure of Human Cyclin-Dependent Kinase 2 in Complex with the Adenine-Derived Inhibitor H717

Dreyer, M., Borcherding, D. R., Dumont, J. A., Peet, N. P., Tsay, J. T., Wright, P. S., Bitonti, A. J., Shen, J., & Kim, S. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm001043t · Cited by 61

3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: A new class of CDK2 inhibitors

Pevarello, P., Fancelli, D., Vulpetti, A., Amici, R., Villa, M., Pittalà, V., Vianello, P., Cameron, A. D., Ciomei, M., Mercurio, C., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.10.071 · Cited by 57

The multiple orthogonal tools approach to define molecular causation in the validation of druggable targets

Hardy, L. W., & Peet, N. P. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02969-6 · Cited by 46

Recent Advances in Cyclin-Dependent Kinase Inhibition. Purine-Based Derivatives as Anti-Cancer Agents. Roles and Perspectives for the Future

Haesslein, J., & Jullian, N. (2002) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026023393291 · Cited by 31

New Targets, Therapies, and Toxicities: Lessons to Be Learned

Stadler, W. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.2408 · Cited by 24

Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes

Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.10.021 · Cited by 886

Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases

Brenk, R., Schipani, A., James, D., Krasowski, A., Gilbert, I. H., Frearson, J., & Wyatt, P. G. (2008) · ChemMedChem · doi:10.1002/cmdc.200700139 · Cited by 709

Properties of FDA-approved small molecule protein kinase inhibitors

Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.006 · Cited by 554

Halogen bonding (X‐bonding): A biological perspective

Scholfield, M. R., Zanden, C. M. V., Carter, M., & Ho, P. S. (2013) · Protein Science · doi:10.1002/pro.2201 · Cited by 451

Nature‐Inspired Construction of MOF@COF Nanozyme with Active Sites in Tailored Microenvironment and Pseudopodia‐Like Surface for Enhanced Bacterial Inhibition

Zhang, L., Liu, Z., Deng, Q., Sang, Y., Dong, K., Ren, J., & Qu, X. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202012487 · Cited by 357